



GLAND PHARMA LIMITED

January 4, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad
Ref: Our Letter dated Aug 25, 2022

Further to our intimation dated August 25, 2022; this is to inform you that following the Pre-Market Inspection covering US FDA's Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the Company's Dundigal Facility at Hyderabad from 22nd August, 2022 to 25th August, 2022; the Company has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection.

Request to take the above information on record.

Yours truly,
For Gland Pharma Limited

P Sampath Kumar
Company Secretary and Compliance Officer